Immutep announces European Patent grant for EFTILAGIMOD ALPHA in Chemo-Immunotherapy

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announce the grant of a new patent (number 3089749) entitled “Combined Preparations for the Treatment of Cancer” by the European Patent Office.

The new patent protects Immutep’s intellectual property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.

Source – https://www.immutep.com/files/content/investor/press-release/2019/1932194.pdf

You Might Also Like